Publications by authors named "M Y Teh"
Gastric cancer (GC) is a major cause of global cancer mortality with high levels of heterogeneity. To explore geospatial interactions in tumor ecosystems, we integrated 2,138 spatial transcriptomic regions-of-interest (ROIs) with 152,423 single-cell expression profiles across 226 GC samples from 121 patients. We observed pervasive expression-based intratumor heterogeneity, recapitulating tumor progression through spatially localized and functionally ordered subgroups associated with specific immune microenvironments, checkpoint profiles, and genetic drivers such as SOX9.
View Article and Find Full Text PDFIntroduction: This study aims to establish, execute, and assess the effectiveness of a perioperative enhanced recovery after surgery (ERAS) clinical care pathway in breast reconstruction patients with LD flap breast cancer treatment. The goal is to improve early recovery outcomes, reduce hospitalization time, and enhance patient satisfaction by implementing a standardized approach to postoperative care.
Methods: This study was conducted at the University of Malaya Medical Center.
Background: The elevation of IQGAP3 expression in diverse cancers indicates a key role for IQGAP3 in carcinogenesis. Although IQGAP3 was established as a proliferating stomach stem cell factor and a regulator of the RAS-ERK pathway, how it drives cancer growth remains unclear.
Objective: We define the function of IQGAP3 in gastric cancer (GC) development and progression.
Artificial intelligence (AI) is revolutionizing head and neck cancer (HNC) care by providing innovative tools that enhance diagnostic accuracy and personalize treatment strategies. This review highlights the advancements in AI technologies, including deep learning and natural language processing, and their applications in HNC. The integration of AI with imaging techniques, genomics, and electronic health records is explored, emphasizing its role in early detection, biomarker discovery, and treatment planning.
View Article and Find Full Text PDFArticle Synopsis
- The study compares the incidence of Level 1 and Level 2 hypoglycaemia in type 2 diabetes patients both with and without chronic kidney disease (CKD).
- A total of 134 participants were monitored using a sensor for two weeks, revealing that those with CKD experienced more frequent hypoglycaemic events than those without.
- The findings suggest that even with similar blood sugar control, CKD patients face a greater risk of nocturnal hypoglycaemia, indicating a need for revised guidelines in managing glucose levels for this group.